XML 82 R60.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration and Profit-Sharing Agreements - Allegran pharmaceuticals strategic alliance and profit sharing agreement (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Aug. 05, 2020
item
Dec. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                        
Revenue recognized   $ 5,767               $ 92,302    
Collaboration and other research and development revenues   11,419 $ 62,841 $ 10,749 $ 5,723 $ 12,284 $ 3,848 $ 2,330 $ 2,069 90,732 $ 20,531 $ 31,937
Deferred revenue   94,927       $ 186,721       94,927 186,721  
Allergan                        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                        
Collaboration and other research and development revenues                   70,600 $ 13,600 $ 21,500
Deferred revenue   0               0    
Allergan | Termination Agreement                        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                        
Termination Agreements, amount payable to Allergan   20,000               20,000    
Termination Agreements, payment made to Allergan                   17,500    
Number of collaboration targets | item 4                      
Fair value of rights to EDIT-101                   5,000    
Allergan | Termination Agreement | Maximum                        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                        
Clinical and regulatory milestone payments for each target program   20,000               20,000    
Aggregated sales milestones payments   90,000               90,000    
Allergan | Strategic Alliance                        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                        
Revenue recognized                   62,100    
Deferred revenue   $ 77,100               77,100    
Fees paid for excess fair value of assets acquired                   $ 15,000